Mesoblast Limited Культура компании

Prof. Silviu Itescu, MBBS (Hons), FRACP, FACP, FACR, FTSE, has been the Chief Executive Officer and Managing Director of Mesoblast Limited since 2011. Prof. Itescu is the Chief Executive Officer at Mesoblast, Inc. He serves as a Director of Transplantation Immunology at Columbia University's New York. Prof. Itescu is the Founder of Mesoblast Limited in 2004 and served as its Chief Scientific Advisor since June 2004. He serves as Professor of Medicine at the University of Melbourne and has an outstanding international reputation in research and development in biotechnology. Prof. Itescu is on the Medical Faculties of both Columbia University in NewYork and Melbourne University. He has established an outstanding international reputation in the fields of Cell Biology, immunology, autoimmune diseases, organ transplantation and heart failure. In these areas of focus, Prof. Itescu has gained broad experience, from basic research in the laboratory through to new drug development and clinical evaluation. He serves as the Chairman and Member of Scientific Advisory Board at Mesoblast Limited. Prof. Itescu han been an Executive Director of Mesoblast Limited since 2007 and served as its director since June 2004. He serves as an Executive Director of Mesoblast, Inc. Prof. Itescu is a member of numerous national and international scientific bodies and professional societies, has consulted globally for many international pharmaceutical companies and has been an advisor to biotechnology and health care investment groups. He served as a Director of Diversa Limited (formelry Ambri Ltd.) from September 18, 2003 to December 20, 2006 and Zenyth Therapeutics Ltd. (formerly Amrad Corp. Ltd.) from July 17, 2003 to November 2006. Prof. Itescu holds a Medical Degree from Monash University and received his Specialty Training in Internal Medicine and Immunology/Rheumatology from New York University.

Mr. Peter Howard, BSc, LLB (Hons), has been the General Counsel and Corporate Executive at Mesoblast, Inc. since July 2011. Mr. Howard serves as General Counsel and Corporate Executive of Mesoblast Limited since July 2011. He served as a Legal and Commercial Manager at the University of Melbourne and assisted the University in the exploitation and commercialization of its intellectual property. Mr. Howard was a Partner in the leading Australian law firm Middleton's where he founded and led their biotechnology practice. He has over 18 years experience in the technology sector advising on intellectual property matters and technology commercialization. He also worked for several years as an executive of a publicly listed company commercializing optical and electron microscopy products, medical devices and cardiovascular clinical trials. At Middleton, he played an integral role in acquisitions and growing some leading Australian public companies such as Mesoblast, Patrys and Evogenix (including merging with Peptech to form Arana and the later take-over by Cephalon). He led the negotiations for Mesoblast in their multi-$ billion deal with Cephalon. He serves as Director of Ausbiotech, Ltd. and Australian Venture Capital Association Limited. He served as a Director of Nexvet Biopharma Public Limited Company. He served as Non-Executive Director of Nexvet Biopharma Pty. Ltd. until September 2014. He is a member of the Institute of Company Directors. He has a Bachelor of Laws (Honours) and Bachelor of Science (Biochemistry).

Mr. Paul Hodgkinson, MA (Hons), FCA, has been the Chief Financial Officer of Mesoblast Limited and Mesoblast, Inc. since June 2014. Mr. Hodgkinson has 16 years of international pharmaceutical experience in the areas of finance, strategic planning, business development and licensing, manufacturing and supply chain and procurement. From 2011 to 2014, Mr. Hodgkinson served as the Country Chief Financial Officer for the Novartis Australia and New Zealand, or ANZ, group of companies and divisions, which was comprised of Alcon, Sandoz and the Novartis Vaccines and Diagnostics, Consumer Health, Animal Health and Pharmaceuticals Divisions. From 1998 to 2006, he held a number of leadership roles with AstraZeneca in the United Kingdom, including Global Licensing Finance Director, before serving as the Chief Financial Officer for AstraZeneca Australia from 2006 to 2011. He served as a Director of Novartis Consumer Health Australasia Pty. Ltd. until June 6, 2014. He is a Member of the Institute of Chartered Accountants in Australia, is a Fellow of the Institute of Chartered Accountants of England and Wales and holds a Master's degree in Engineering from Cambridge University. He has also undertaken executive leadership programs at the Harvard Business School and INSEAD.

Mr. Jonathan Richard Symonds, also known as Jon, CBE, BA, FCA, serves as Head of Corporate Finance & Strategy at Mesoblast Limited. Mr. Symonds serves as Senior Advisor at GHO Capital Partners LLP. He serves as the Chief Financial Officer at Novartis Institutes for BioMedical Research, Inc. since September 1, 2009. He serves as Deputy Chief Financial Officer at Novartis Vaccines and Diagnostics, Inc. He joined Mesoblast as an advisor in 2014. He served as the Chief Financial Officer of Novartis AG from 2010 to May 1, 2013. He served as an Advisor of Novartis AG since May 1, 2013. He was a Partner and Managing Director of Goldman Sachs from 2007 to 2009. He served as Managing Director at The Goldman Sachs Group Inc. He served as Deputy Chief Financial Officer at Novartis AG. He was Partner and Managing Director in the Investment Banking Division at Goldman Sachs in the United Kingdom. He served as Chief Financial Officer at AstraZeneca PLC from 1997 to July 2007 and was responsible for strategy, including mergers & acquisitions, licensing and business development; investor relations; purchasing and information systems. He has eight years of experience as Chief Financial Officer of AstraZeneca and served positions as Group Finance Director at Zeneca and partner at KPMG. Prior to joining AstraZeneca in 1997, he was a Partner at KPMG. He joined KPMG in 1980. He served as Group Finance Director at Zeneca. In 1985 he spent two years in the US working on a number of projects involving SEC securities registrations. On returning from the US, Mr. Symonds began to specialize in the chemicals and pharmaceuticals sector and in 1991 was seconded to ICI to help the Board with the separation of the chemicals and pharmaceuticals businesses, which ultimately formed Zeneca. Thereafter, he spent four years working first with Shell in the Hague and then with Hoechst in Frankfurt, advising them on major structural changes and strategic business. He has been the Chairman of Proteus Digital Health, Inc. since November 2015. He served as the Chairperson at Innocoll Holdings plc (formerly known as Innocoll AG) from March 16, 2016 to July 24, 2017. He served as the Chairperson of Supervisory Board at Innocoll AG (formerly Innocoll GmbH) since May 2014 until March 16, 2016. He has been Chairman of the Board of HSBC Bank Plc since April 14, 2014. He serves as Chairman of the 100 Group of Finance Directors. He serves as Non-Executive Director of Qinetiq Plc. He serves as board member of the Accounting Standards Board and founder of the Oxford University Centre for Business Taxation Research. He has been an Independent Non-Executive Director of HSBC Holdings plc since April 14, 2014 and has been its Senior Independent Non-Executive Director since April 28, 2017. He serves as a Director of Novartis Venture Funds. He has been a Director of Proteus Digital Health, Inc. since June 2014. He served as a Director of Non-Executive Diageo PLC from May 1, 2004 to October 16, 2007. He served as an Executive Director of AstraZeneca PLC from October 1, 1997 to July, 2007 with overall responsibility for Information Services. He served as Director of Qinetiq Group Plc until June 30, 2004. He is a Member of the Accounting Standards Board's Urgent Issues Task Force and is joint Chairman of the Business Tax Forum. He qualified as a Chartered Accountant in 1982. He was awarded a Commander of the British Empire (CBE) for service to industry in the 2007 New Year's honors list. Mr. Symonds holds a BA with a first class degree in business finance from the University of Hertfordshire, UK, in 1980. He also received an honorary doctorate.

Dr. Suzanne Lipe, BSc (Hons), Ph.D., LLB serves as the Chief Executive Officer at Prota Therapeutics Pty Ltd. She served as the Vice President of Operations at Mesoblast Limited since March 18, 2008. Dr. Lipe served as the Chief Operating Officer at Norwood Immunology Limited. She has strong development and commercial experience gained over almost 20 years in the pharmaceutical and biotech industry. She has negotiated with centres, set up and managed preclinical and clinical trial programs, including IND multi-centre studies, and had regulatory affairs responsibility for several multinational companies. Through a strong commercial focus, she developed the strategy and managed the launch of new products on to the market, particularly through her senior roles with AstraZeneca, Rhone-Poulenc Rorer (now Aventis) and CSL. Dr. Lipe has been the Managing Director, Chief Executive Officer and Board member of three biotechnology start-up companies and for four years. She is a member of the Pharmaceuticals Partnerships Program Committee of the Innovation Board (AusIndustry).

Dr. Eric Strati, Pharm.D., MBA serves as the Head of Commercial at Mesoblast Limited. Dr. Strati has over 17 years of experience across a broad range of industries within the healthcare sector including pharmaceutical, biotechnology, investment banking and pharmacy benefit management. Prior to joining Mesoblast in 2015, Dr. Strati held various commercial leadership roles including new product planning, lifecycle management, sales, marketing and payer strategy. Previous positions include most recently as Executive Director of Managed Markets at Novartis, medical affairs positions at Genzyme and Bristol-Myers Squibb and Vice President of Global Pharmaceutical Equity Research at HSBC. He earned his Bachelors of Science in Pharmacy and MBA in Health Systems Management from Union University and Doctor of Pharmacy from University of Kansas.

Dr. John D. McMannis, Ph.D., has been the Head of Manufacturing at Mesoblast Limited and Mesoblast, Inc. since 2011. Dr. McMannis serves as an Executive Vice President of Manufacturing at Mesoblast Limited. He was a Director of Cellular Therapy Laboratory, Department of Stem Cell Transplantation, Division of Cancer Medicine at University of Texas MD Anderson Cancer Center, Houston, Texas and the Technical Director of the Cord Blood Bank. Prior to this, He was at the Immunotherapy Division of Baxter and COBE BCT (now Terumo BCT). For the past 25 years, He has been involved in clinical cellular therapy trials in both academic and commercial environments and is considered an expert in translational research and large scale manufacturing. He has served on a number of Scientific Advisory Boards and Board of Directors for commercial entities and organizations in the cellular field. He has been a Member of Scientific Advisory Board of BioLife Solutions, Inc. since January 2012.

Dr. Donna L. Skerrett, M.D., MS, has been the Chief Medical Officer of Mesoblast Limited and Mesoblast, Inc. since 2011. Dr. Skerrett has 20 years of combined experience in transfusion medicine, cellular therapy and transplantation. Dr. Skerrett served as Head of Clinical & Regulatory Affairs of Mesoblast Limited since 2004. She served as Medical Director and Head of Regulatory of Mesoblast Limited since 2009 and 2008 respectively. She served as an Executive of Clinical & Regulatory Affairs of Mesoblast. She has been involved in stem cell procurement, manipulation and transplantation for more than 10 years. She served as Director of the Stem Cell Facilities at Weill-Cornell Medical Center in New York from 2004 to 2011 and previously served as Associate Director of Transfusion Medicine at Columbia University's New York-Presbyterian Hospital from 1999 to 2004. She oversees clinical development of the antibody-based stem cell selection technology and in vitro culture processes, as well as the human clinical trial programs, while liaising closely with the FDA. She serves as a Director of Alliance for Regenerative Medicine. She is an Advisor to the New York State Department of Health on the progenitor cell committee since 1989 and the governor's Council on Blood and Transfusion Services since 2007. Dr. Skerrett has been an adviser and committee member with the National Marrow Donor Program and the American Society of Hematology.

Ms. Geraldine Storton, Bsc, MMS, MBA, serves as Head of Regulatory Affairs and Quality Management at Mesoblast Limited. Ms. Storton joined Mesoblast in December 2015. She is a seasoned pharmaceutical executive with more than 24 years' experience across the full value chain of Pharmaceutical and Medical Device Research and Development, production and commercialization worldwide. She has an extensive background in regulatory affairs and quality and as a consultant to cell therapy companies. Ms. Storton held executive roles at Hospira and its predecessor companies in both regulatory affairs and quality, with a focus on major program management. She served as Vice President of Program Management, Quality at Hospira headquarters in Chicago and she led a company-wide quality remediation program to improve compliance in manufacturing across 15 facilities worldwide. As Regional Director of Commercial Quality ANZ, Asia and Japan, Ms. Storton was responsible for quality oversight and management of all products sold in Asia Pacific countries. Her responsibilities included regulatory compliance, batch release, field actions, complaints management, change control, due diligence and new product launch. As Director of global regulatory operations, Ms. Storton managed development and registration of new products and on-market management of the existing product portfolio for all Hospira's products developed or manufactured within Asia Pacific for global distribution.

Mr. Michael Schuster, MS, BSc, MBA serves as Head of Pharma Partnering at Mesoblast Limited. Mr. Schuster served as the Head of New Product, Technology Evaluation & Investor Relations at Mesoblast Limited. Mr. Schuster served as an Executive Vice President of Therapeutic Business Units at Mesoblast Limited. He served as Vice President of North America at Mesoblast Limited. He served as Vice President of operations at North America at Mesoblast Ltd.